Recruiting

Testing a new cell therapy for three autoimmune diseases

Plain-English translation of NCT07295847 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage study testing , a new type of cell therapy that works by modifying your own immune cells to help control autoimmune diseases. The trial is enrolling about 27 adults across three diseases — systemic sclerosis, idiopathic inflammatory myopathies, and difficult-to-treat rheumatoid arthritis — to see if this treatment is safe and to find the right dose for future studies.

Current treatments for these autoimmune diseases don't work well enough for many patients, and some people stop responding over time. This medication takes a different approach by reprogramming immune cells to reduce the harmful immune response that damages your body.

Do you qualify?

You likely qualify if…

you are 18 years or older with a confirmed diagnosis of systemic sclerosis, inflammatory muscle disease, or severe rheumatoid arthritis that hasn't responded well to standard treatments
you are in good enough physical health to safely receive the treatment, as determined by your doctor
you are willing and able to stay near the research site for at least 28 days after receiving the treatment
you are able to use effective birth control during the study and for at least one year after treatment
you can give informed consent and are willing to follow all study instructions

You likely don't qualify if…

you have a BMI below 18 or above 35
you have ever received any type of CAR T-cell therapy before
you have received an organ or bone marrow transplant or are on a transplant waiting list
you have a serious heart condition, require oxygen at rest, or have uncontrolled high blood pressure
you have HIV, active hepatitis, active syphilis, or any untreated active infection

What participation looks like

The study will collect your own immune cells through a procedure, then grow and modify them in a laboratory before infusing them back into your body. You'll receive one of two treatment regimens and will need to stay close to the research site for the first month to be monitored for safety. The trial will track how you respond and any side effects over time to help determine the best dose for future studies of this treatment.

AI-generated summary from trial data · Jul 1, 2026 · Not medical advice

Trial locations(22 sites)

United States

Research Site, Tucson, Arizona

Research Site, Stanford, California

Research Site, Chicago, Illinois

Research Site, Ann Arbor, Michigan

Research Site, St Louis, Missouri